FLT3 Inhibitors Upregulate CXCR4 and E-selectin Ligands Via ERK Suppression in AML Cells and CXCR4/E-selectin Inhibition Enhances Anti-leukemia Efficacy of FLT3-targeted Therapy in AML

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2023 Apr 21

PMID 37085610

Authors

Yannan Jia

Weiguo Zhang

Mahesh Basyal

Kyung Hee Chang

Lauren Ostermann

Jared K Burks

Charlie Ly

Hong Mu-Mosley

Qi Zhang

Xin Han

William E Fogler

John L Magnani

Arnaud Lesegretain

Anna A Zal

Tomasz Zal

Michael Andreeff

Affiliations

Soon will be listed here.

Citing Articles

Small Extracellular Vesicles from Breast Cancer Cells Induce Cardiotoxicity.

Osorio-Mendez J, Gomez-Grosso L, Montoya-Ortiz G, Novoa-Herran S, Dominguez-Romero Y Int J Mol Sci. 2025; 26(3).

PMID: 39940718 PMC: 11816698. DOI: 10.3390/ijms26030945.

Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia.

Boueya I, Sandhow L, Albuquerque J, Znaidi R, Passaro D Leukemia. 2024; 39(1):8-24.

PMID: 39528790 PMC: 11717709. DOI: 10.1038/s41375-024-02453-x.

Overexpression of Nrf2 in bone marrow mesenchymal stem cells promotes B-cell acute lymphoblastic leukemia cells invasion and extramedullary organ infiltration through stimulation of the SDF-1/CXCR4 axis.

Zheng L, Pan C, Ma D, Shang Q, Hu T, Zhang T Front Pharmacol. 2024; 15:1393482.

PMID: 39081954 PMC: 11286583. DOI: 10.3389/fphar.2024.1393482.

Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?.

Uy G, DeAngelo D, Lozier J, Fisher D, Jonas B, Magnani J Blood Rev. 2024; 65:101184.

PMID: 38493006 PMC: 11051645. DOI: 10.1016/j.blre.2024.101184.

The Rac1-inhibitor EHop-016 attenuates AML cell migration and enhances the efficacy of daunorubicin in MOLM-13 transplanted zebrafish larvae.

Hemsing A, Forde J, Reikvam H, Herfindal L Transl Oncol. 2024; 40:101876.

PMID: 38185059 PMC: 10818244. DOI: 10.1016/j.tranon.2024.101876.

References

Kottaridis P, Gale R, Linch D . Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk Lymphoma. 2003; 44(6):905-13. DOI: 10.1080/1042819031000067503. View

Kennedy V, Smith C . Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Front Oncol. 2021; 10:612880. PMC: 7787101. DOI: 10.3389/fonc.2020.612880. View

Zhang W, Konopleva M, Shi Y, McQueen T, Harris D, Ling X . Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008; 100(3):184-98. DOI: 10.1093/jnci/djm328. View

Tabe Y, Konopleva M . Role of Microenvironment in Resistance to Therapy in AML. Curr Hematol Malig Rep. 2015; 10(2):96-103. PMC: 4447522. DOI: 10.1007/s11899-015-0253-6. View

Lapidot T, Dar A, Kollet O . How do stem cells find their way home?. Blood. 2005; 106(6):1901-10. DOI: 10.1182/blood-2005-04-1417. View

Winkler I, Barbier V, Nowlan B, Jacobsen R, Forristal C, Patton J . Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat Med. 2012; 18(11):1651-7. DOI: 10.1038/nm.2969. View

Wang G, Jiang B, Rue E, Semenza G . Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92(12):5510-4. PMC: 41725. DOI: 10.1073/pnas.92.12.5510. View

Spoo A, Lubbert M, Wierda W, Burger J . CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2006; 109(2):786-91. DOI: 10.1182/blood-2006-05-024844. View

Bruno S, Mancini M, De Santis S, Monaldi C, Cavo M, Soverini S . The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities. Int J Mol Sci. 2021; 22(13). PMC: 8269413. DOI: 10.3390/ijms22136857. View

10.

Borthakur G, Ofran Y, Tallman M, Foran J, Uy G, Dipersio J . BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer. 2020; 127(8):1246-1259. DOI: 10.1002/cncr.33338. View

11.

Crawford J, Dale D, Lyman G . Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004; 100(2):228-37. DOI: 10.1002/cncr.11882. View

12.

Behrens K, Alexander W . Cytokine control of megakaryopoiesis. Growth Factors. 2018; 36(3-4):89-103. DOI: 10.1080/08977194.2018.1498487. View

13.

Brouard N, Chapel A, Granotier C, Khazaal I, Peault B, Thierry D . Transplantation of stromal cells transduced with the human IL3 gene to stimulate hematopoiesis in human fetal bone grafts in non-obese, diabetic-severe combined immunodeficiency mice. Leukemia. 1998; 12(7):1128-35. DOI: 10.1038/sj.leu.2401081. View

14.

Burdach S . The granulocyte/macrophage-colony stimulating factor (GM-CSF): basic science and clinical application. Klin Padiatr. 1991; 203(4):302-10. DOI: 10.1055/s-2007-1025445. View

15.

Warkentin A, Lopez M, Lasater E, Lin K, He B, Leung A . Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife. 2014; 3. PMC: 4307180. DOI: 10.7554/eLife.03445. View